{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219610","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2026-05-12T20:31:11+00:00","discovered_at":"2026-05-12T20:32:00.302255+00:00","generated_at":"2026-05-12T20:32:41.032819+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Inhibikase Q1 2026 net loss $16.4M; first patient enrolled in Phase 3 PAH study IMPROVE-PAH","bullets":["Net loss $16.4M ($0.10 EPS) vs $13.7M ($0.15) in Q1 2025; cash & equivalents $170.4M as of Mar 31, 2026.","First patient enrolled in registrational Phase 3 IMPROVE-PAH study for IKT-001 in PAH; EMA approved 12 EU countries, total 16 countries.","R&D expenses $10.8M (incl. one-time non-cash $7.4M from CorHepta acquisition in prior year); SG&A $7.4M.","Upcoming presentations at ATS May 17 and 20, 2026 on safety/tolerability/PK and preclinical efficacy of IKT-001."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219610","json":"https://secwatch.observer/filing/0001193125-26-219610.json","markdown":"https://secwatch.observer/filing/0001193125-26-219610.md","text":"https://secwatch.observer/filing/0001193125-26-219610.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/0001193125-26-219610-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/d119997d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T20:32:41.032819+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9708ba097a02ab672406b3bf807215c794e25f9c","claim":"Inhibikase Therapeutics, Inc. reported the quarter ended March 31, 2026 results: net income $16.4 million, or $0.10 per share, EPS $0.10 per share.","evidence_excerpt":"Net loss for the quarter ended March 31, 2026, was $16.4 million, or $0.10 per share, compared to a net loss of $13.7 million, or $0.15 per share in the quarter ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/0001193125-26-219610-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2026"},{"label":"Net income","value":"$16.4 million, or $0.10 per share"},{"label":"EPS","value":"$0.10 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}